Actively Recruiting
The Effect of Probiotics ATG-F4 in Cancer Patients
Led by Chungnam National University Hospital · Updated on 2024-05-31
30
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
Sponsors
C
Chungnam National University Hospital
Lead Sponsor
A
AtoGen Co. Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
Patients with advanced colorectal cancer or pancreatic cancer who are receiving oxaliplatin-based chemotherapy will be included. The research participants in this study will consume probiotics along with safety and anti-cancer agent side effect-related questionnaires, blood, and fecal sample collection for up to 12 weeks from the date of registration. The total duration of participation for research subjects is 12 weeks.
CONDITIONS
Official Title
The Effect of Probiotics ATG-F4 in Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with advanced colorectal cancer or pancreatic cancer who are undergoing treatment with Oxaliplatin-based chemotherapy at Chungnam National University Hospital, including both newly diagnosed and recurrent cases.
- Aged 19 years or older.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 points.
- Expected life expectancy of at least 3 months.
- Ability to understand the requirements of the clinical trial and willingness to sign the informed consent form.
You will not qualify if you...
- Presence of known brain metastases.
- Malignant bowel obstruction requiring surgical intervention.
- Uncontrolled, active infections, symptomatic congestive heart failure, unstable angina, cardiac arrhythmias, or any psychiatric/social conditions that may limit compliance with the study requirements.
- Partial or complete intestinal obstruction.
- Pregnant or lactating women.
- Use of antibiotics, antifungals, or antiviral agents on more than one occasion within the past month.
- Consumption of probiotics products or fermented milk more than twice within the past month.
- Patients with neurological or psychiatric disorders.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chungnam National University Hospital
Daejeon, South Korea, 35015
Actively Recruiting
Research Team
H
Hyewon Ryu, Professor
CONTACT
S
Sora Kang, clinical professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here